secwatch.observer — SEC 8-K summary
======================================

Issuer:     Passage BIO, Inc. (PASG)
CIK:        0001787297
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001558370-23-018679
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Passage Bio reports Q3 net loss of $27.1M; cash runway into Q4 2025, clinical data on track
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities of $132.8M as of Sept 30, 2023; cash runway extended into Q4 2025.
- Net loss of $27.1M ($0.49 per share) for Q3 2023, comparable to $26.7M ($0.49) in Q3 2022.
- R&D expenses $15.1M; G&A expenses $8.2M, down from $10.7M due to workforce reductions.
- Initial safety and biomarker data from three Cohort 1 patients in PBFT02 (FTD-GRN) trial expected in Q4 2023.
- GM1 trial (Imagine-1) treating multiple patients at Dose 3; initial safety/biomarker data from Dose 3 expected mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787297/000155837023018679/0001558370-23-018679-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787297/000155837023018679/pasg-20231113x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-018679

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer